RG
Redmile Group Portfolio holdings
AUM
$940M
This Quarter Return
-3.24%
1 Year Return
+75.78%
3 Year Return
+543.67%
5 Year Return
+585.96%
10 Year Return
+6,653.82%
AUM
$5.73B
AUM Growth
+$5.73B
(-15%)
Cap. Flow
-$198M
Cap. Flow
% of AUM
-3.45%
Top 10 Holdings %
Top 10 Hldgs %
44.42%
Holding
91
New
5
Increased
15
Reduced
36
Closed
16
Top Buys
| 1 |
Invivyd
IVVD
|
$137M |
| 2 |
Absci
ABSI
|
$93.4M |
| 3 |
LivaNova
LIVN
|
$85.5M |
| 4 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
$49.2M |
| 5 |
Stevanato
STVN
|
$30M |
Top Sells
| 1 |
DexCom
DXCM
|
$98.4M |
| 2 |
ZY
Zymergen Inc. Common Stock
ZY
|
$60.9M |
| 3 |
SelectQuote
SLQT
|
$46.5M |
| 4 |
Charles River Laboratories
CRL
|
$40.1M |
| 5 |
Cigna
CI
|
$37.9M |
Sector Composition
| 1 | Healthcare | 93.97% |
| 2 | Consumer Staples | 3.39% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$120M
| $768M | 13.39% | 12,957,222 | – | – |
|
|
ALLK
2
DELISTED
Allakos
ALLK
| $226M | 3.94% | 2,131,796 -85,200 | -4% | -$9.02M |
|
|
IGMS
3
DELISTED
IGM Biosciences
IGMS
| $225M | 3.93% | 3,425,455 | – | – |
|
4
argenx
ARGX
$43.6B
| $221M | 3.85% | 730,582 -59,700 | -8% | -$18M |
|
5
ADC Therapeutics
ADCT
$345M
| $204M | 3.57% | 7,529,329 +7,300 | +0.1% | +$198K |
|
6
Amicus Therapeutics
FOLD
$2.34B
| $199M | 3.46% | 20,799,303 | – | – |
|
7
The Beauty Health Co
SKIN
$264M
| $194M | 3.39% | 7,483,706 +1,130,460 | +18% | +$29.4M |
|
|
8
LivaNova
LIVN
$3.08B
| $174M | 3.03% | 2,191,019 +1,079,335 | +97% | +$85.5M |
|
9
Beam Therapeutics
BEAM
$1.66B
| $172M | 3% | 1,975,006 -77,500 | -4% | -$6.74M |
|
10
Celldex Therapeutics
CLDX
$1.47B
| $164M | 2.87% | 3,043,298 +31,217 | +1% | +$1.69M |
|
11
Kymera Therapeutics
KYMR
$2.95B
| $164M | 2.86% | 2,793,708 +262,200 | +10% | +$15.4M |
|
|
NVTA
12
DELISTED
Invitae Corporation
NVTA
| $151M | 2.64% | 5,317,477 +670,084 | +14% | +$19.1M |
|
|
13
Invivyd
IVVD
$204M
| $137M | 2.39% | +3,246,960 | New | +$137M |
|
|
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $137M | 2.39% | 4,031,521 -213,200 | -5% | -$7.24M |
|
15
Replimune Group
REPL
$422M
| $121M | 2.11% | 4,078,112 -113,400 | -3% | -$3.36M |
|
16
Atara Biotherapeutics
ATRA
$84.6M
| $116M | 2.02% | 6,466,277 +16,700 | +0.3% | +$299K |
|
17
Shattuck Labs
STTK
$47M
| $115M | 2% | 5,619,914 | – | – |
|
18
Jazz Pharmaceuticals
JAZZ
$7.75B
| $112M | 1.96% | 861,401 +1,300 | +0.2% | +$169K |
|
19
Krystal Biotech
KRYS
$4.27B
| $104M | 1.81% | 1,982,432 -89,700 | -4% | -$4.68M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $99.7M | 1.74% | 587,374 -184,011 | -24% | -$31.2M |
|
|
21
Absci
ABSI
$357M
| $93.4M | 1.63% | +8,031,094 | New | +$93.4M |
|
22
Nurix Therapeutics
NRIX
$714M
| $92.7M | 1.62% | 3,093,077 -97,000 | -3% | -$2.91M |
|
|
VERV
23
DELISTED
Verve Therapeutics
VERV
| $87.8M | 1.53% | 1,869,030 -67,500 | -3% | -$3.17M |
|
24
Scholar Rock
SRRK
$3.14B
| $84.2M | 1.47% | 2,550,205 +243,177 | +11% | +$8.03M |
|
25
Regenxbio
RGNX
$451M
| $84.2M | 1.47% | 2,008,001 -130,200 | -6% | -$5.46M |
|